Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) Return on Sales: 2019-2025

Historic Return on Sales for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to -1.70%.

  • Cidara Therapeutics' Return on Sales fell 201.00% to -1.70% in Q1 2025 from the same period last year, while for Mar 2025 it was -1.70%, marking a year-over-year decrease of 201.00%. This contributed to the annual value of 0.36% for FY2024, which is 27.00% up from last year.
  • As of Q1 2025, Cidara Therapeutics' Return on Sales stood at -1.70%, which was down 6,249.92% from 0.03% recorded in Q2 2024.
  • Cidara Therapeutics' Return on Sales' 5-year high stood at 0.31% during Q1 2024, with a 5-year trough of -6.35% in Q1 2021.
  • In the last 3 years, Cidara Therapeutics' Return on Sales had a median value of 0.03% in 2024 and averaged -0.18%.
  • As far as peak fluctuations go, Cidara Therapeutics' Return on Sales plummeted by 456bps in 2021, and later soared by 542bps in 2022.
  • Over the past 5 years, Cidara Therapeutics' Return on Sales (Quarterly) stood at -0.94% in 2021, then soared by 34bps to -0.60% in 2022, then skyrocketed by 90bps to 0.29% in 2023, then fell by 15bps to 0.03% in 2024, then plummeted by 201bps to -1.70% in 2025.
  • Its last three reported values are -1.70% in Q1 2025, 0.03% for Q2 2024, and 0.31% during Q1 2024.